Regen BioPharma Inc (RGBP)

[Schuller]

Just to clear up a few points and keep the board straight.

When the sum of 500M was mentioned it was Dr Koos talking about DcellVac. His comment was that companies with a cancer treatment in clinical trials tend to be valued about half a billion dollars. Regen has not got DcellVac to clinical yet and the earliest would be spring.

The reason it was put on hold was to use funds to push Hema as that would bring the first company sale and fund all their research.

Having NR2F6 was always going to be the golden egg and now that they have found two separate receptors all energy is being focused on that. Companies that have found this match and taken it to clinical trial have fetched billions. Regen feel they can be in the 3-5 billion range if they can successfully take NR2F6 through clinical 1. For those keeping score a billion buyout would yield approx $3.50 per share.

There will be no buyout for at least 12 months but I believe a big partnership is in the works and that would eventually lead to a buyout for a successful trial.

Best regards and the best of luck!
Schuller.